Organoidsciences Ltd.
KKRX:4760406,100.00
KRW
+130.00
(+2.18%)
ISIN
KR7476040001
Return %
Stock
S&P 500
1Y
-82.84
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 89
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Cheongju-si South Korea
- IPO Date
- May 9, 2025
- Website
- organoidrx.com
- Similar Companies
- Business
- Organoidsciences Ltd. is a South Korea-based biotechnology company specializing in the development of adult stem cell-derived organoid regenerative therapeutics and organoid-based drug discovery and evaluation platforms. Founded in 2018 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, with additional manufacturing and research facilities in Cheongju-si, the company operates across the regenerative medicine, biopharmaceutical contract research, precision oncology, and life science research reagents sectors. The company offers a comprehensive portfolio spanning therapeutic pipelines, contract testing services, and laboratory consumables: its Advanced Tissue-derived Organoid Regenerative Medicine (ATORM) platform comprises regenerative cell therapeutics designed to restore damaged tissues, featuring lead candidate ATORM-C for radiation-induced proctitis and inflammatory bowel diseases including Crohn's disease and ulcerative colitis, ATORM-S for radiation-induced salivary gland hypofunction and Sjögren's syndrome, and ATORM-E for endometrial disorders; its Organoid-based Drug Discovery and Evaluation System (ODISEI) platform provides high-throughput drug screening, ex vivo patient-derived organoid (PDO) efficacy testing, ADME/toxicity profiling, and customized disease modeling services serving as non-animal testing alternatives for oncology, infectious disease, dermatological, and functional food development; and its research materials division manufactures GelMatrix extracellular matrix hydrogels, organoEZ specialized cell culture media and differentiation kits, growth factors, primary cell isolation reagents, and customized organoid biobanking solutions. Organoidsciences Ltd. serves global pharmaceutical corporations, biotechnology developers, academic research institutions, clinical hospitals, and cosmetic enterprises across South Korea, North America, Europe, and Southeast Asia, supported by international operational initiatives including its Southeast Asian branch venture VOS Discovery. Recent major corporate developments include the listing of the company's equity on the Korea Exchange (KRX: 476040) following the completion of its initial public offering on the KOSDAQ market; the designation of its proprietary organoid therapeutic platform as a National Advanced Strategic Technology by the Ministry of Trade, Industry and Energy of South Korea; the initiation and advancement of Phase 1 clinical studies and advanced regenerative medicine clinical research programs for lead candidate ATORM-C; strategic collaborative agreements with domestic and international hospital networks to expand patient-derived organoid biobanks; and the commercial expansion of its preclinical testing services and organoid consumable distribution networks into overseas biotechnology markets.